Department of Biochemistry, School of Molecular and Systems Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2H7.
J Mol Cell Cardiol. 2010 May;48(5):925-33. doi: 10.1016/j.yjmcc.2010.01.016. Epub 2010 Jan 29.
The solution structure of Ca(2+)-bound regulatory domain of cardiac troponin C (cNTnC) in complex with the switch region of troponin I (cTnI(147-163)) and the calmodulin antagonist, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfinamide (W7), has been determined by NMR spectroscopy. The structure reveals that the W7 naphthalene ring interacts with the terminal methyl groups of M47, M60, and M81 as well as aliphatic and aromatic side chains of several other residues in the hydrophobic pocket of cNTnC. The H3 ring proton of W7 also contacts the methyl groups of I148 and M153 of cTnI(147-163). The N-(6-aminohexyl) tail interacts primarily with the methyl groups of V64 and M81, which are located on the C- and D-helices of cNTnC. Compared to the structure of the cNTnCCa(2+)W7 complex (Hoffman, R. M. B. and Sykes, B. D. (2009) Biochemistry 48, 5541-5552), the tail of W7 reorients slightly toward the surface of cNTnC while the ring remains in the hydrophobic pocket. The positively charged -NH(3)(+) group from the tail of W7 repels the positively charged R147 of cTnI(147-163). As a result, the N-terminus of the peptide moves away from cNTnC and the helical content of cTnI(147-163) is diminished, when compared to the structure of cNTnCCa(2+)cTnI(147-163) (Li, M. X., Spyracopoulos, L., and Sykes B. D. (1999) Biochemistry 38, 8289-8298). Thus the ternary structure cNTnCCa(2+)W7cTnI(147-163) reported in this study offers an explanation for the approximately 13-fold affinity reduction of cTnI(147-163) for cNTnCCa(2+) in the presence of W7 and provides a structural basis for the inhibitory effect of W7 in cardiac muscle contraction. This generates molecular insight into structural features that are useful for the design of cTnC-specific Ca(2+)-desensitizing drugs.
通过 NMR 光谱学确定了 Ca(2+)-结合的心脏肌钙蛋白 C(cNTnC)调节域与肌钙蛋白 I(cTnI(147-163))的开关区和钙调蛋白拮抗剂 N-(6-氨基己基)-5-氯-1-萘磺酰胺(W7)的复合物的溶液结构。该结构表明,W7 萘环与 cNTnC 疏水口袋中 M47、M60 和 M81 的末端甲基以及几个其他残基的脂族和芳族侧链相互作用。W7 的 H3 环质子还与 cTnI(147-163)的 I148 和 M153 的甲基接触。N-(6-氨基己基)尾主要与 cNTnC 的 C-和 D-螺旋上的 V64 和 M81 的甲基相互作用。与 cNTnCCa(2+)W7 复合物的结构(Hoffman,R.M.B.和 Sykes,B.D.(2009)Biochemistry 48,5541-5552)相比,W7 的尾部略微朝向 cNTnC 的表面重新定向,而环仍留在疏水性口袋中。W7 尾部的带正电荷的-NH(3)(+)基团排斥 cTnI(147-163)的带正电荷的 R147。因此,与 cNTnCCa(2+)cTnI(147-163)的结构相比,肽的 N 端远离 cNTnC,并且 cTnI(147-163)的螺旋含量减少(Li,M.X.,Spyracopoulos,L.和 Sykes B.D.(1999)Biochemistry 38,8289-8298)。因此,本研究中报道的三元结构 cNTnCCa(2+)W7cTnI(147-163)为 cTnI(147-163)与 W7 存在时对 cNTnCCa(2+)的亲和力降低约 13 倍提供了解释,并为 W7 在心肌收缩中的抑制作用提供了结构基础。这为设计针对 cTnC 的特异性 Ca(2+)-脱敏药物提供了对结构特征的分子见解。